Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

Smart ProTcell Smart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy platform for fast and durable immune system reconstitution

Coordinator
Smart Immune, France
Runs
1 June 2023 to 30 November 2025
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190102812

What the project is doing

In the project's own words, from its summary on CORDIS.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used in immunodeficiencies & blood malignancies though costly, hard-to-access & linked to many severe complications. Smart Immune puts forth a high-profile solution to solve this gap: ProTcell platform supplies clinical-grade, allogeneic lymphoid progenitor cells produced in just 7 days ex-vivo. These are made into tolerant polyclonal mature T cells by the patients own thymus in a record <3 months (vs. 15-24 months naturally), & reducing complications since infused in our 1st patient (June 2020).

With strong IP, orphan drug label secured & traction across eminent KOLs in >7 countries, we face a window opportunity. With the EICs support, we pursue the less attractive-to-VCs SCID indication, as part of our Series A, to become a front row T-cell therapy player, with future chimeric antigen receptor (CAR) therapies in mind. We project to treat >40k patients by 2030 & recover a ROI of 5,28 over our target Series A.

Topics

Who is involved

OrganisationCityCountryRole
Smart ImmuneParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI